Alterations of T-cell-mediated immunity in acute myeloid leukemia.
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
15
11
2019
accepted:
20
02
2020
revised:
14
02
2020
pubmed:
5
3
2020
medline:
1
12
2020
entrez:
5
3
2020
Statut:
ppublish
Résumé
Acute myeloid leukemia (AML) is a systemic, heterogeneous hematologic malignancy with poor overall survival. While some malignancies have seen improvements in clinical outcomes with immunotherapy, success of these agents in AML remains elusive. Despite limited progress, stem cell transplantation and donor lymphocyte infusions show that modulation of the immune system can improve overall survival of AML patients. Understanding the causes of immune evasion and disease progression will identify potential immune-mediated targets in AML. This review explores immunosuppressive mechanisms that alter T-cell-mediated immunity in AML.
Identifiants
pubmed: 32127646
doi: 10.1038/s41388-020-1239-y
pii: 10.1038/s41388-020-1239-y
pmc: PMC7234277
mid: NIHMS1588004
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3611-3619Subventions
Organisme : NCI NIH HHS
ID : K12 CA090625
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL138291
Pays : United States
Organisme : NHLBI NIH HHS
ID : L30 HL139435
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA217834
Pays : United States
Références
Howlader NNA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, et al. SEER Cancer Statistics Review, 1975–2016. Bethesda, MD: National Cancer Institute.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21. https://doi.org/10.1056/NEJMoa1516192 .
doi: 10.1056/NEJMoa1516192
pubmed: 27276561
pmcid: 4979995
Pollyea DA. New drugs for acute myeloid leukemia inspired by genomics and when to use them. Hematology. 2018;2018:45–50. https://doi.org/10.1182/asheducation-2018.1.45 .
doi: 10.1182/asheducation-2018.1.45
pubmed: 30504290
Cerrano M, Itzykson R. New treatment options for acute myeloid leukemia in 2019. Curr Oncol Rep. 2019;21:16. https://doi.org/10.1007/s11912-019-0764-8 .
doi: 10.1007/s11912-019-0764-8
pubmed: 30715623
Lamble AJ, Lind EF. Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity. Front Oncol. 2018;8:213. https://doi.org/10.3389/fonc.2018.00213 .
doi: 10.3389/fonc.2018.00213
pubmed: 29951373
pmcid: 6008423
Austin R, Smyth MJ, Lane SW. Harnessing the immune system in acute myeloid leukaemia. Crit Rev Oncol/Hematol. 2016;103:62–77. https://doi.org/10.1016/j.critrevonc.2016.04.020 .
doi: 10.1016/j.critrevonc.2016.04.020
Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.
doi: 10.1182/blood.V75.3.555.555
Boddu P, Kantarjian H, Garcia-Manero G, Allison J, Sharma P, Daver N. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk lymphoma. 2018;59:790–802. https://doi.org/10.1080/10428194.2017.1344905 .
doi: 10.1080/10428194.2017.1344905
pubmed: 28679300
Liu Y, Bewersdorf JP, Stahl M, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era? Blood Rev. 2019;34:67–83. https://doi.org/10.1016/j.blre.2018.12.001 .
doi: 10.1016/j.blre.2018.12.001
pubmed: 30553527
Buggins AG, Milojkovic D, Arno MJ, Lea NC, Mufti GJ, Thomas NS. et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J Immunol. 2001;167:6021–30.
doi: 10.4049/jimmunol.167.10.6021
Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 2009;114:3909–16. https://doi.org/10.1182/blood-2009-02-206946 .
doi: 10.1182/blood-2009-02-206946
pubmed: 19710498
pmcid: 2773481
Barosi G. An immune dysregulation in MPN. Curr Hematol Malig Rep. 2014;9:331–9. https://doi.org/10.1007/s11899-014-0227-0 .
doi: 10.1007/s11899-014-0227-0
pubmed: 25139710
Fozza C, Crobu V, Isoni MA, Dore F. The immune landscape of myelodysplastic syndromes. Crit Rev Oncol/Hematol. 2016;107:90–9. https://doi.org/10.1016/j.critrevonc.2016.08.016 .
doi: 10.1016/j.critrevonc.2016.08.016
Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34 https://doi.org/10.1186/s13073-017-0424-2 .
doi: 10.1186/s13073-017-0424-2
pubmed: 28420421
pmcid: 5395719
Klco JM, Spencer DH, Miller CA, Griffith M, Lamprecht TL, O’Laughlin M, et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell. 2014;25:379–92. https://doi.org/10.1016/j.ccr.2014.01.031 .
doi: 10.1016/j.ccr.2014.01.031
pubmed: 24613412
pmcid: 3983786
Hersh EM, Whitecar JP Jr., McCredie KB, Bodey GP Sr., Freireich EJ. Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia. N Engl J Med 1971;285:1211–6. https://doi.org/10.1056/nejm197111252852201 .
doi: 10.1056/nejm197111252852201
pubmed: 5286519
Hersh EM, Gutterman JU, Mavligit GM, McCredie KB, Burgess MA, Matthews A, et al. Serial studies of immunocompetence of patients undergoing chemotherapy for acute leukemia. J Clin Investig. 1974;54:401–8. https://doi.org/10.1172/jci107775 .
doi: 10.1172/jci107775
pubmed: 4527189
Rashidi A, Fisher SI. Spontaneous remission of acute myeloid leukemia. Leuk lymphoma. 2015;56:1727–34. https://doi.org/10.3109/10428194.2014.970545 .
doi: 10.3109/10428194.2014.970545
pubmed: 25284494
Muller-Schmah C, Solari L, Weis R, Pfeifer D, Scheibenbogen C, Trepel M, et al. Immune response as a possible mechanism of long-lasting disease control in spontaneous remission of MLL/AF9-positive acute myeloid leukemia. Ann Hematol. 2012;91:27–32. https://doi.org/10.1007/s00277-011-1332-y .
doi: 10.1007/s00277-011-1332-y
pubmed: 21959947
Hasegawa K, Tanaka S, Fujiki F, Morimoto S, Nakajima H, Tatsumi N, et al. An immunocompetent mouse model for MLL/AF9 leukemia reveals the potential of spontaneous cytotoxic T-cell response to an antigen expressed in leukemia cells. PLoS ONE. 2015;10:e0144594. https://doi.org/10.1371/journal.pone.0144594 .
doi: 10.1371/journal.pone.0144594
pubmed: 26658107
pmcid: 4684241
Zhang L, Chen X, Liu X, Kline DE, Teague RM, Gajewski TF, et al. CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Investig. 2013;123:1999–2010. https://doi.org/10.1172/jci63980.
doi: 10.1172/jci63980.
pubmed: 23619361
Almosailleakh M, Schwaller J. Murine models of acute myeloid leukaemia. Int J Mol Sci. 2019;20. https://doi.org/10.3390/ijms20020453 .
Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307. https://doi.org/10.1038/nri1806 .
doi: 10.1038/nri1806
pubmed: 16557261
Teague RM, Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J Immunother Cancer. 2013;1. https://doi.org/10.1186/2051-1426-1-13 .
Wang X, Zheng J, Liu J, Yao J, He Y, Li X, et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol. 2005;75:468–76. https://doi.org/10.1111/j.1600-0609.2005.00537.x . e-pub ahead of print.
doi: 10.1111/j.1600-0609.2005.00537.x
pubmed: 16313258
Tian T, Yu S, Liu L, Xue F, Yuan C, Wang M, et al. The profile of T helper subsets in bone marrow microenvironment is distinct for different stages of acute myeloid leukemia patients and chemotherapy partly ameliorates these variations. PLoS ONE. 2015; 10. https://doi.org/10.1371/journal.pone.0131761 .
Williams P, Basu S, Garcia-Manero G, Hourigan CS, Oetjen KA, Cortes JE, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2018. https://doi.org/10.1002/cncr.31896 .
doi: 10.1002/cncr.31896
pubmed: 30521100
pmcid: 6786263
van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176:1265–81.e1224. https://doi.org/10.1016/j.cell.2019.01.031 .
doi: 10.1016/j.cell.2019.01.031
pubmed: 30827681
pmcid: 6515904
Ustun C, Miller JS, Munn DH, Weisdorf DJ, Blazar BR. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood. 2011;118:5084–95. https://doi.org/10.1182/blood-2011-07-365817 .
doi: 10.1182/blood-2011-07-365817
pubmed: 21881045
pmcid: 3217399
Ersvaer E, Liseth K, Skavland J, Gjertsen BT, Bruserud O. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol. 2010;11:38. https://doi.org/10.1186/1471-2172-11-38 .
doi: 10.1186/1471-2172-11-38
pubmed: 20618967
pmcid: 2912832
Kanakry CG, Hess AD, Gocke CD, Thoburn C, Kos F, Meyer C, et al. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 2011;117:608–17. https://doi.org/10.1182/blood-2010-04-277939 .
doi: 10.1182/blood-2010-04-277939
pubmed: 20935254
pmcid: 3031483
Lichtenegger FS, Lorenz R, Gellhaus K, Hiddemann W, Beck B, Subklewe M. Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. Leuk Res. 2014;38:964–9. https://doi.org/10.1016/j.leukres.2014.05.014 .
doi: 10.1016/j.leukres.2014.05.014
pubmed: 24957413
Shenghui Z, Yixiang H, Jianbo W, Kang Y, Laixi B, Yan Z, et al. Elevated frequencies of CD4(+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia. Int J Cancer. 2011;129:1373–81. https://doi.org/10.1002/ijc.25791 .
doi: 10.1002/ijc.25791
pubmed: 21105040
Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A. et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res. 2009;15:3325–32. https://doi.org/10.1158/1078-0432.Ccr-08-3010 .
doi: 10.1158/1078-0432.Ccr-08-3010
pubmed: 19417016
pmcid: 3700356
Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, et al. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood. 2009;114:3793–802. https://doi.org/10.1182/blood-2009-03-208181 .
doi: 10.1182/blood-2009-03-208181
pubmed: 19724059
pmcid: 2773484
Kittang AO, Kordasti S, Sand KE, Costantini B, Kramer AM, Perezabellan P, et al. Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome. Oncoimmunology. 2016;5:e1062208. https://doi.org/10.1080/2162402x.2015.1062208 .
doi: 10.1080/2162402x.2015.1062208
pubmed: 27057428
Menter T, Kuzmanic B, Bucher C, Medinger M, Halter J, Dirnhofer S, et al. Beneficial role of increased FOXP3(+) regulatory T-cells in acute myeloid leukaemia therapy response. Br J Haematol. 2018;182:581–3. https://doi.org/10.1111/bjh.14819 .
doi: 10.1111/bjh.14819
pubmed: 28653378
Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol. 2015;8:93. https://doi.org/10.1186/s13045-015-0189-2 .
doi: 10.1186/s13045-015-0189-2
pubmed: 26219463
pmcid: 4518596
Sun YX, Kong HL, Liu CF, Yu S, Tian T, Ma DX, et al. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. Hum Immunol. 2014;75:113–8. https://doi.org/10.1016/j.humimm.2013.11.014 .
doi: 10.1016/j.humimm.2013.11.014
pubmed: 24269703
Musuraca G, De Matteis S, Napolitano R, Papayannidis C, Guadagnuolo V, Fabbri F, et al. IL-17/IL-10 double-producing T cells: new link between infections, immunosuppression and acute myeloid leukemia. J Transl Med. 2015;13:229. https://doi.org/10.1186/s12967-015-0590-1 .
doi: 10.1186/s12967-015-0590-1
pubmed: 26174551
pmcid: 4502949
Tian T, Yu S, Wang M, Yuan C, Zhang H, Ji C. et al. Aberrant T helper 17 cells and related cytokines in bone marrow microenvironment of patients with acute myeloid leukemia. Clin Dev Immunol. 2013;2013:915873. https://doi.org/10.1155/2013/915873 .
doi: 10.1155/2013/915873
pubmed: 24023567
pmcid: 3759248
Han Y, Ye A, Bi L, Wu J, Yu K, Zhang S. Th17 cells and interleukin-17 increase with poor prognosis in patients with acute myeloid leukemia. Cancer Sci. 2014;105:933–42. https://doi.org/10.1111/cas.12459 .
doi: 10.1111/cas.12459
pubmed: 24890519
pmcid: 4317867
Wu C, Wang S, Wang F, Chen Q, Peng S, Zhang Y, et al. Increased frequencies of T helper type 17 cells in the peripheral blood of patients with acute myeloid leukaemia. Clin Exp Immunol. 2009;158:199–204. https://doi.org/10.1111/j.1365-2249.2009.04011.x .
doi: 10.1111/j.1365-2249.2009.04011.x
pubmed: 19737137
pmcid: 2768809
Wherry EJ. T cell exhaustion. Nat Immunol. 2011;12:492–9.
doi: 10.1038/ni.2035
Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117:4501–10. https://doi.org/10.1182/blood-2010-10-310425 .
doi: 10.1182/blood-2010-10-310425
pubmed: 21385853
pmcid: 3099570
Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562:605–9. https://doi.org/10.1038/s41586-018-0615-z .
doi: 10.1038/s41586-018-0615-z
pubmed: 30333625
pmcid: 6296374
LaBelle JL, Hanke CA, Blazar BR, Truitt RL. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia. Blood. 2002;99:2146–53.
doi: 10.1182/blood.V99.6.2146
Knaus HA, Berglund S, Hackl H, Blackford AL, Zeidner JF, Montiel-Esparza R, et al. Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapy. JCI Insight. 2018;3. https://doi.org/10.1172/jci.insight.120974 .
Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G. et al. CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol. 2018;190:64–73. https://doi.org/10.1016/j.clim.2017.08.021 .
doi: 10.1016/j.clim.2017.08.021
pubmed: 28893624
Dama P, Tang M, Fulton N, Kline J, Liu H. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy. J Immunother Cancer. 2019;7:175. https://doi.org/10.1186/s40425-019-0611-3 .
doi: 10.1186/s40425-019-0611-3
pubmed: 31291985
pmcid: 6621946
Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE. et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science. 2012;338:1220–5. https://doi.org/10.1126/science.1229620 .
doi: 10.1126/science.1229620
pubmed: 23197535
pmcid: 3653769
Jia B, Wang L, Claxton DF, Ehmann WC, Rybka WB, Mineishi S, et al. Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients. Blood Cancer J. 2018;8:34. https://doi.org/10.1038/s41408-018-0069-4 .
doi: 10.1038/s41408-018-0069-4
pubmed: 29563517
pmcid: 5862839
Jia B, Zhao C, Rakszawski KL, Claxton DF, Ehmann WC, Rybka WB, et al. Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia (AML). Cancer Res. 2019. https://doi.org/10.1158/0008-5472.Can-18-3107 .
doi: 10.1158/0008-5472.Can-18-3107
pubmed: 31615812
pmcid: 6810597
Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, et al. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9:370–83. https://doi.org/10.1158/2159-8290.Cd-18-0774 .
doi: 10.1158/2159-8290.Cd-18-0774
pubmed: 30409776
Masarova L, Kantarjian H, Ravandi F, Sharma P, Garcia-Manero G, Daver N. Update on immunotherapy in AML and MDS: monoclonal antibodies and checkpoint inhibitors paving the road for clinical practice. In: Naing A, Hajjar J, editors. Immunotherapy. Cham: Springer International Publishing; 2018. p. 97–116.
Lee JB, Chen B, Vasic D, Law AD, Zhang L. Cellular immunotherapy for acute myeloid leukemia: how specific should it be? Blood Rev. 2019;35:18–31. https://doi.org/10.1016/j.blre.2019.02.001 .
doi: 10.1016/j.blre.2019.02.001
pubmed: 30826141
Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia. Blood. 2016;127:42–52. https://doi.org/10.1182/blood-2015-07-604512 .
doi: 10.1182/blood-2015-07-604512
pubmed: 26660432
Kelderman S, Schumacher TN, Haanen JB. Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol. 2014;8:1132–9. https://doi.org/10.1016/j.molonc.2014.07.011 .
doi: 10.1016/j.molonc.2014.07.011
pubmed: 25106088
pmcid: 5528612
Philip M, Fairchild L, Sun L, Horste EL, Camara S, Shakiba M, et al. Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature. 2017;545:452–6. https://doi.org/10.1038/nature22367 .
doi: 10.1038/nature22367
pubmed: 28514453
pmcid: 5693219
Radpour R, Riether C, Simillion C, Hopner S, Bruggmann R, Ochsenbein AF CD8(+) T cells expand stem and progenitor cells in favorable but not adverse risk acute myeloid leukemia. Leukemia 2019. https://doi.org/10.1038/s41375-019-0441-9 .
Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196:459–68.
doi: 10.1084/jem.20020121
Curti A, Aluigi M, Pandolfi S, Ferri E, Isidori A, Salvestrini V, et al. Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme indoleamine 2,3-dioxygenase. Leukemia. 2007;21:353–5. https://doi.org/10.1038/sj.leu.2404485 .
doi: 10.1038/sj.leu.2404485
pubmed: 17170728
Fukuno K, Hara T, Tsurumi H, Shibata Y, Mabuchi R, Nakamura N. et al. Expression of indoleamine 2,3-dioxygenase in leukemic cells indicates an unfavorable prognosis in acute myeloid leukemia patients with intermediate-risk cytogenetics. Leuk Lymphoma. 2015;56:1398–405. https://doi.org/10.3109/10428194.2014.953150 .
doi: 10.3109/10428194.2014.953150
pubmed: 25248875
Chamuleau ME, van de Loosdrecht AA, Hess CJ, Janssen JJ, Zevenbergen A, Delwel R, et al. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. Haematologica. 2008;93:1894–8. https://doi.org/10.3324/haematol.13113 .
doi: 10.3324/haematol.13113
pubmed: 19050070
Corm S, Berthon C, Imbenotte M, Biggio V, Lhermitte M, Dupont C, et al. Indoleamine 2,3-dioxygenase activity of acute myeloid leukemia cells can be measured from patients’ sera by HPLC and is inducible by IFN-gamma. Leuk Res. 2009;33:490–4. https://doi.org/10.1016/j.leukres.2008.06.014 .
doi: 10.1016/j.leukres.2008.06.014
pubmed: 18639339
Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood. 2007;109:2871–7. https://doi.org/10.1182/blood-2006-07-036863 .
doi: 10.1182/blood-2006-07-036863
Arandi N, Ramzi M, Safaei F, Monabati A. Overexpression of indoleamine 2,3-dioxygenase correlates with regulatory T cell phenotype in acute myeloid leukemia patients with normal karyotype. Blood Res. 2018;53:294–8. https://doi.org/10.5045/br.2018.53.4.294 .
doi: 10.5045/br.2018.53.4.294
pubmed: 30588466
pmcid: 6300669
Mussai F, De Santo C, Abu-Dayyeh I, Booth S, Quek L, McEwen-Smith RM, et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood. 2013;122:749–58. https://doi.org/10.1182/blood-2013-01-480129 .
doi: 10.1182/blood-2013-01-480129
pubmed: 23733335
pmcid: 3731930
Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, et al. Targeting the arginine metabolic brake enhances immunotherapy for leukaemia. Int J Cancer. 2018. https://doi.org/10.1002/ijc.32028 .
Orleans-Lindsay JK, Barber LD, Prentice HG, Lowdell MW. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function–implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol. 2001;126:403–11.
doi: 10.1046/j.1365-2249.2001.01692.x
Losman JA, Looper RE, Koivunen P, Lee S, Schneider RK, McMahon C, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339:1621–5.
doi: 10.1126/science.1231677
Medeiros BC, Fathi AT, DiNardo CD, Pollyea DA, Chan SM, Swords R. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31:272–81. https://doi.org/10.1038/leu.2016.275 .
doi: 10.1038/leu.2016.275
pubmed: 27721426
DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, et al. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013;121:4917–24. https://doi.org/10.1182/blood-2013-03-493197 .
doi: 10.1182/blood-2013-03-493197
pubmed: 23641016
pmcid: 3682342
Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. 2018;24:1192–203. https://doi.org/10.1038/s41591-018-0095-6 .
doi: 10.1038/s41591-018-0095-6
pubmed: 29988124
Zhang L, Sorensen MD, Kristensen BW, Reifenberger G, McIntyre TM, Lin F. D-2-hydroxyglutarate is an intercellular mediator in IDH-mutant gliomas inhibiting complement and T cells. Clin Cancer Res. 2018;24:5381–91. https://doi.org/10.1158/1078-0432.Ccr-17-3855 .
doi: 10.1158/1078-0432.Ccr-17-3855
pubmed: 30006485
pmcid: 6214730
Xu T, Stewart KM, Wang X, Liu K, Xie M, Ryu JK, et al. Metabolic control of TH17 and induced Treg cell balance by an epigenetic mechanism. Nature. 2017;548:228–33. https://doi.org/10.1038/nature23475 .
doi: 10.1038/nature23475
pubmed: 28783731
pmcid: 6701955
Kang X, Kim J, Deng M, John S, Chen H, Wu G. et al. Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors. Cell Cycle. 2016;15:25–40. https://doi.org/10.1080/15384101.2015.1121324 .
doi: 10.1080/15384101.2015.1121324
pubmed: 26636629
Dobrowolska H, Gill KZ, Serban G, Ivan E, Li Q, Qiao P, et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation. Cytom Part B Clin Cytom. 2013;84:21–9. https://doi.org/10.1002/cyto.b.21050 .
doi: 10.1002/cyto.b.21050
Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. 2007;21:566–8. https://doi.org/10.1038/sj.leu.2404559 .
doi: 10.1038/sj.leu.2404559
Damiani D, Tiribelli M, Raspadori D, Sirianni S, Meneghel A, Cavalllin M, et al. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. Oncotarget. 2015;6:30212–21. https://doi.org/10.18632/oncotarget.4901 .
doi: 10.18632/oncotarget.4901
pubmed: 26338961
pmcid: 4745791
Zahran AM, Mohammed Saleh MF, Sayed MM, Rayan A, Ali AM, Hetta HF. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. Cancer Biomark. 2018;22:587–95. https://doi.org/10.3233/cbm-181368 .
doi: 10.3233/cbm-181368
pubmed: 29843224
Coles SJ, Hills RK, Wang EC, Burnett AK, Man S, Darley RL, et al. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells. Leukemia. 2012;26:2146–8. https://doi.org/10.1038/leu.2012.75 .
doi: 10.1038/leu.2012.75
pubmed: 22430636
pmcid: 3460214
Coles SJ, Hills RK, Wang EC, Burnett AK, Man S, Darley RL, et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia. 2012;26:2148–51.
doi: 10.1038/leu.2012.77
Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, et al. CD200 is a new prognostic factor in multiple myeloma. Blood. 2006;108:4194–7. https://doi.org/10.1182/blood-2006-06-029355 .
doi: 10.1182/blood-2006-06-029355
pubmed: 16946299
Moreaux J, Veyrune JL, Reme T, De Vos J, Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun. 2008;366:117–22. https://doi.org/10.1016/j.bbrc.2007.11.103 .
doi: 10.1016/j.bbrc.2007.11.103
pubmed: 18060862
Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D. et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol. 2007;178:5595–605. https://doi.org/10.4049/jimmunol.178.9.5595 .
doi: 10.4049/jimmunol.178.9.5595
pubmed: 17442942
Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol. 2008;29:464–8. https://doi.org/10.1016/j.it.2008.07.005 .
doi: 10.1016/j.it.2008.07.005
pubmed: 18775673
Christopher MJ, Petti AA, Rettig MP, Miller CA, Chendamarai E, Duncavage EJ, et al. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. N. Engl J Med. 2018;379:2330–41. https://doi.org/10.1056/NEJMoa1808777 .
doi: 10.1056/NEJMoa1808777
pubmed: 30380364
pmcid: 6322675
Tikhonova AN, Dolgalev I, Hu H, Sivaraj KK, Hoxha E, Cuesta-Domínguez Á, et al. The bone marrow microenvironment at single-cell resolution. Nature 2019. https://doi.org/10.1038/s41586-019-1104-8 .